Mechanism of growth inhibitory effect of Blumea balsamifera extract in hepatocellular carcinoma

Bioscience, Biotechnology and Biochemistry

Volumn 72, Issue 5, 2008, Pages 1183-1189

  Norikura, Toshio ^a   Kojima Yuasa, Akiko ^a   Shimizu, Miki ^a   Huang, Xuedan ^a   Xu, Shenghui ^a   Kametani, Saeda ^a   Rho, Sook Nyung ^b   Kennedy, David Opare ^a   Matsui Yuasa, Isao ^a  

^a Osaka Prefecture University   (Japan)

^b Chung Ang University   (South Korea)

Author keywords

Blumea balsamifera; Cell cycle; Cyclin E; Proliferation inducing ligand (APRIL); Retinoblastoma protein (Rb)

Indexed keywords

CHEMICAL REACTIONS; DRUG THERAPY; GROWTH KINETICS; MECHANISMS; PHOTOACOUSTIC EFFECT;

ANTICANCER ACTIVITIES; CANCER PATIENTS; CELL CYCLE ARREST; CELL MODELING; HEPATOCELLULAR CARCINOMA (HCC); INHIBITORY ACTIVITIES; INHIBITORY EFFECTS; RAT HEPATOCYTES; RETINOBLASTOMA (RB) PROTEINS; TUMOR CELLS;

CELL GROWTH;

ALCOHOL; APRIL PROTEIN; CYCLIN E; GROWTH INHIBITOR; METHANOL; NUCLEIC ACID SYNTHESIS INHIBITOR; PLANT EXTRACT;

ANIMAL; ARTICLE; ASTERACEAE; CELL CYCLE; CELL PROLIFERATION; CELL SURVIVAL; CHEMISTRY; DRUG EFFECT; GENE EXPRESSION REGULATION; GENETICS; HUMAN; LIVER CELL CARCINOMA; METABOLISM; PATHOLOGY; PHOSPHORYLATION; PROTEIN PROCESSING; RAT; RETINOBLASTOMA; TUMOR CELL LINE;

ANIMALS; ASTERACEAE; CARCINOMA, HEPATOCELLULAR; CELL CYCLE; CELL LINE, TUMOR; CELL PROLIFERATION; CELL SURVIVAL; CYCLIN E; ETHANOL; GENE EXPRESSION REGULATION, NEOPLASTIC; GROWTH INHIBITORS; HUMANS; METHANOL; NUCLEIC ACID SYNTHESIS INHIBITORS; PHOSPHORYLATION; PLANT EXTRACTS; PROTEIN PROCESSING, POST-TRANSLATIONAL; RATS; RETINOBLASTOMA; TUMOR NECROSIS FACTOR LIGAND SUPERFAMILY MEMBER 13;

BLUMEA BALSAMIFERA; RATTUS;

EID: 45749113300     PISSN: 09168451     EISSN: 13476947     Source Type: Journal    
DOI: 10.1271/bbb.70586     Document Type: Article

References (30)

1. Roberts, L. R., and Gores, G. J., Hepatocellular carcinoma: molecular pathways and new therapeutic targets. Semin. Liver Dis., 25, 212-225 (2005).
2. Llovet, J. M., Bustamante, J., Castells, A., Vilana, R., Ayuso Mdel, C., Sala, M., Bru, C., Rodes, J., and Bruix, J., Natural history of untreated nonsurgical hepatocellular carcinoma: rationale for the design and evaluation of therapeutic trials. Hepatology (Baltimore), 29, 62-67 (1999).
3. Newman, D. J., Cragg, G. M., and Snader, K. M., Natural products as sources of new drugs over the period 1981-2002. J. Nat. Prod., 66, 1022-1037 (2003).
4. Osaki, N., Koyano, T., Kowithayakorn, T., Hayashi, M., Komiyama, K., and Ishibashi, M., Sesquiterpenoids and plasmin-inhibitory flavonoids from Blumea balsamifera. J. Nat. Prod., 68, 447-449 (2005).
5. Ragasa, C. Y., Co, A. L., and Rideout, J. A., Antifungal metabolites from Blumea balsamifera. Nat. Prod. Res., 19, 231-237 (2005).
6. Xu, S. B., Chen, W. F., Liang, H. Q., Lin, Y. C., Deng, Y. J., and Long, K. H., Protective action of blumeatin against experimental liver injuries. Zhongguo Yao Li Xue Bao (Acta Pharmacol. Sin.), 14, 376-378 (1993).
7. Hasegawa, H., Yamada, Y., Komiyama, K., Hayashi, M., Ishibashi, M., Yoshida, T., Sakai, T., Koyano, T., Kam, T. S., Murata, K., Sugahara, K., Tsuruda, K., Akamatsu, N., Tsukasaki, K., Masuda, M., Takasu, N., and Kamihira, S., Dihydroflavonol BB-1, an extract of natural plant Blumea balsamifera, abrogates TRAIL resistance in leukemia cells. Blood, 107, 679-688 (2006).
8. Kennedy, D. O., Kojima, A., Moffatt, J., Yamagiwa, H., Yano, Y., Hasuma, T., Otani, S., and Matsui-Yuasa, I., Cellular thiol status-dependent inhibition of tumor cell growth via modulation of retinoblastoma protein phosphorylation by (-)-epigallocatechin. Cancer Lett., 179, 25-32 (2002).
9. Arimura, T., Kojima-Yuasa, A., Suzuki, M., Kennedy, D. O., and Matsui-Yuasa, I., Caspase-independent apoptosis induced by evening primrose extract in Ehrlich ascites tumor cells. Cancer Lett., 201, 9-16 (2003).
10. Huang, X., Kojima-Yuasa, A., Norikura, T., Kennedy, D. O., Hasuma, T., and Matsui-Yuasa, I., Mechanism of the anti-cancer activity of Zizyphus jujuba in HepG2 cells. Am. J. Chinese Med., 35, 517-532 (2007).
11. Hahne, M., Kataoka, T., Schroter, M., Hofmann, K., Irmler, M., Bodmer, J. L., Schneider, P., Bornand, T., Holler, N., French, L. E., Sordat, B., Rimoldi, D., and Tschopp, J., APRIL, a new ligand of the tumor necrosis factor family, stimulates tumor cell growth. J. Exp. Med., 188, 1185-1190 (1998).
12. Ware, C. F., APRIL and BAFF connect autoimmunity and cancer. J. Exp. Med., 192, F35-38 (2000).
13. Okano, H., Shiraki, K., Yamanaka, Y., Inoue, H., Kawakita, T., Saitou, Y., Yamaguchi, Y., Enokimura, N., Ito, K., Yamamoto, N., Sugimoto, K., Murata, K., and Nakano, T., Functional expression of a proliferation-related ligand in hepatocellular carcinoma and its implications for neovascularization. World J. Gastroenterol., 11, 4650-4654 (2005).
14. Anagnostopoulou, M. A., Kefalas, P., Papageorgiou, V. P., Assimopoulou, A. N., and Boskou, D., Radical scavenging activity of various extracts and fractions of sweet orange peel (Citrus sinensis). Food Chem., 94, 19-25 (2006).
15. Moldeus, P., Hogberg, J., and Orrenius, S., Isolation and use of liver cells. Methods Enzymol., 52, 60-71 (1978).
16. Zhang, S. Z., Lipsky, M. M., Trump, B. F., and Hsu, I. C., Neutral red (NR) assay for cell viability and xenobiotic-induced cytotoxicity in primary cultures of human and rat hepatocytes. Cell Biol. Toxicol., 6, 219-234 (1990).
17. Ko, S. Y., Lin, S. C., Chang, K. W., Liu, C. J., Chang, S. S., Lu, S. Y., and Liu, T. Y., Modulation of KGF-1 gene expression in oral fibroblasts by ripe areca nut extract. J. Oral Pathol. Med., 32, 399-407 (2003).
18. Hsu, S. M., and Soban, E., Color modification of diaminobenzidine (DAB) precipitation by metallic ions and its application for double immunohistochemistry. J. Histochem. Cytochem., 30, 1079-1082 (1982).
19. Bradford, M. M., A rapid and sensitive method for the quantitation of microgram quantities of protein utilizing the principle of protein-dye binding. Anal. Biochem., 72, 248-254 (1976).
20. Lopez-Fraga, M., Fernandez, R., Albar, J. P., and Hahne, M., Biologically active APRIL is secreted following intracellular processing in the Golgi apparatus by furin convertase. EMBO Rep., 2, 945-951 (2001).
21. Senderowicz, A. M., The cell cycle as a target for cancer therapy: basic and clinical findings with the small molecule inhibitors flavopiridol and UCN-01. Oncologist, 7 (Suppl 3), 12-19 (2002).
22. Semenov, I., Akyuz, C., Roginskaya, V., Chauhan, D., and Corey, S. J., Growth inhibition and apoptosis of myeloma cells by the CDK inhibitor flavopiridol. Leuk. Res., 26, 271-280 (2002).
23. Stadler, W. M., Vogelzang, N. J., Amato, R., Sosman, J., Taber, D., Liebowitz, D., and Vokes, E. E., Flavopiridol, a novel cyclin-dependent kinase inhibitor, in metastatic renal cancer: a University of Chicago Phase II Consortium study. J. Clin. Oncol., 18, 371-375 (2000).
24. Hanahan, D., and Weinberg, R. A., The hallmarks of cancer. Cell, 100, 57-70 (2000).
25. Kato, J., Matsushime, H., Hiebert, S. W., Ewen, M. E., and Sherr, C. J., Direct binding of cyclin D to the retinoblastoma gene product (pRb) and pRb phosphorylation by the cyclin D-dependent kinase CDK4. Genes Dev., 7, 331-342 (1993).
26. Helin, K., Regulation of cell proliferation by the E2F transcription factors. Curr. Opin. Genet. Dev., 8, 28-35 (1998).
27. Matsumoto, Y., Hayashi, K., and Nishida, E., Cyclin-dependent kinase 2 (Cdk2) is required for centrosome duplication in mammalian cells. Curr. Biol., 9, 429-432 (1999).
28. Okuda, M., Horn, H. F., Tarapore, P., Tokuyama, Y., Smulian, A. G., Chan, P. K., Knudsen, E. S., Hofmann, I. A., Snyder, J. D., Bove, K. E., and Fukasawa, K., Nucleophosmin/B23 is a target of CDK2/cyclin E in centrosome duplication. Cell, 103, 127-140 (2000).
29. Stein, J. V., Lopez-Fraga, M., Elustondo, F. A., Carvalho-Pinto, C. E., Rodriguez, D., Gomez-Caro, R., De Jong, J., Martinez, A. C., Medema, J. P., and Hahne, M., APRIL modulates B and T cell immunity. J. Clin. Invest., 109, 1587-1598 (2002).
30. Dillon, S. R., Gross, J. A., Ansell, S. M., and Novak, A. J., An APRIL to remember: novel TNF ligands as therapeutic targets. Nat. Rev., 5, 235-246 (2006).